Skip to content
Open access

Subregional reduction in CB1 receptor in dopamine neurons in postmortem schizophrenia midbrain.

Aug 2026 · Schizophrenia Research · Vol 297, pp. 182-190 · 0 citations · 61 references
Medicine

TL;DR

Subregional differences within the midbrain, with no change in the VTA, are demonstrated, and the substantia nigra undergoes the prominent molecular changes in Schizophrenia are provided, providing insight into the spatial molecular pathology of the midbrain in schizophrenia.

Abstract

Schizophrenia is a chronic psychiatric disorder affecting 1% of the population. Common treatment strategies include antipsychotics that block or modulate dopamine receptors. However, ∼34% of patients exhibit resistance to current antipsychotic medications targeting dopaminergic receptors, which are central to the pathophysiology of psychosis. Consequently, research has focused on alternative modulators of dopamine signaling. The cannabinoid receptor 1 (CB1) has the potential to neuromodulate neurons. CB1 expression in dopamine neurons and reactive GFAP+ astrocytes is altered in schizophrenia. Here, we examined CB1 expressions in dopamine neurons and reactive GFAP+ astrocytes using immunofluorescent staining in post-mortem human midbrain tissue from individuals with schizophrenia (n = 9) and matched controls (n = 10). As previously established, within the substantia nigra we report no change in dopamine neurons and increased number of astrocytes. No changes were found in the ventral tegmental area (VTA). Upon subregional analysis of the substantia nigra, there was decreased CB1 expression on dopamine neurons in the medial and ventral subregions of the substantia nigra. Notably, astrocyte density increased specifically in the dorsal subregion, with no change in astrocytic CB1. These findings demonstrate subregional differences within the midbrain, with no change in the VTA, and that the substantia nigra undergoes the prominent molecular changes in Schizophrenia. Overall, it provides insight into the spatial molecular pathology of the midbrain in schizophrenia.

Read PDF

Similar papers

Open access Sep 2026

243. Dysconnectivity in schizophrenia: evidence at the molecular level via a network analysis of postmortem tissues

A reorganization of molecular networks in schizophrenia is demonstrated, with alterations in the micro-architecture of molecular couplings, strengthening the importance of investigating functional interactions among molecules, as such analyses may reveal significant alterations in schizophrenia that cannot be detected...

G. De Simone, T. Nuzzo, A. di Maio et al. · 0 citations
Open access Aug 2026

Neuronal Ddit4 Overexpression in the Medial Prefrontal Cortex Reduces Synaptic Density and Impairs Cognitive Function in Mice

It is demonstrated that Ddit4 overexpression specifically in neurons is sufficient to reduce spine density in the PFC, impair temporal order memory, and induce transcriptional changes associated with stress and depression.

Alexander M. Kuhn, Kelly E. Bosis, Madeline M. Mairose et al. · 0 citations
Open access Sep 2026

Mesocortical dopamine hypofunction and prefrontal plasticity deficits in the cuprizone model.

It is suggested that cuprizone-induced intoxication disrupts VTA-mPFC circuitry, leading to mesocortical dopamine hypofunction, altered cortical plasticity, and executive dysfunction, and support targeting mesocortical dopamine transmission as a potential strategy for MS-related cognitive symptoms.

Laura Dazzi, G. Talani, F. Biggio et al. · 0 citations
Open access Sep 2026

790. How can we protet D-neuron?

Abstract Background In humans, the D-neuron system in nucleus accumbens (D16), projection field of mesolimbic dopamine (DA) system, is far developed than in other animal species. "D-cell hypothesis of schizophrenia" (Ikemoto K., Lancet, 2025) has shown the lack of D-neurons in the D16 of post-mortem brains of schizophr...

K. Ikemoto · 0 citations
Editorial Sep 2026

Hippocampal mechanisms and neural circuitry of negative symptoms in schizophrenia.

This work proposes a two-dimensional clinical framework for negative symptoms to better understand their neurobiological mechanism, by segregating symptoms into diminished expressivity and amotivation domains and explores how biological sex serves as a critical factor of individual variability in symptom expression.

D. Uliana, Anthony A. Grace · 0 citations
Open access Sep 2026

Enantiomer-specific modulation of GABAA receptors differentially regulates stress-induced dopamine dysregulation.

It is indicated that stereochemical and subunit-selective modulation of GABAA receptors critically determines circuit-level outcomes following stress and reinforce α5-GABAA receptors as a key target for normalizing hippocampal-driven dopamine system dysfunction associated with psychosis-relevant states.

Kayla Lilly, Prithu Mondal, James M. Cook et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.